The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial showed that the pharmacological blockage of IL-1β protected from recurrent atherothrombotic cardiovascular events in patients with a history of myocardial infarction, independently of its lipid lowering-effects (28, 29). The gene discussed is IL1B; the disease is deep vein thrombosis.